If anything, the molecular biologists I know are discouraged by the size of the problem being solved relative to the number of people working on it-

The main question is the value of a marginal molecular biologist chipping away at the problems with current methods.

All those new knowledge about genes we got through the human genome project produces few promising leads for new drugs. Big Pharma companies sit on large pile of cash at a time where the interest rates are near zero and they buy back shares while laying off scientists.

Currently we don't know what 1/4 to 1/3 of the human genes do. Those where we do know a function might have additional functions. With a lot of hard work we might find out more functions, but that doesn't bring us much further. Few get a few new drug targets but drug targets aren't the limiting factor for drug discovery. Predicting which drugs actually help is the more important issues as clinical trials are really expensive. Most drugs put into clinical trials fail.

Apart from the actual use of the science, progress is hold back by poor ability to replicate findings. Some of that is because scientists don't work properly but it can also be that the monoclonal antibody you order today is not the same as the one that you ordered a month ago even through you ordered it from the same lab and it has the same label.

Then even if your finding is correct and you publish it, that doesn't mean that your paper is going to be read. The language in which papers are written is very complicated and not easily interpretable by computers.